Comparison of the second consensus statement with the movement disorder society criteria for multiple system atrophy: A single-center analysis

Sun, Yan; Sun, Wei; Wei, Luhua; Li, Fan; Jiang, Yanyan; Zhai, Fei; Luan, Mingyue; Chen, Jing; Wang, Zhaoxia

doi:10.1016/j.parkreldis.2022.105242

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address these potential limitations and enhance the sensitivity of early diagnosis of MSA, a movement disorder society (MDS) MSA Criteria Revision Task Force was convened to develop novel MSA diagnostic criteria (Wenning et al, 2022 (Sun et al, 2023). However, they did not compare the sensitivity and specificity of the two diagnostic criteria and the sample size was small.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic utility of movement disorder society criteria for multiple system atrophy

Zhang

Hou

Wei

et al. 2023

Front. Aging Neurosci.

View full text Add to dashboard Cite

BackgroundThe 2008 criteria for the diagnosis of multiple system atrophy (MSA) has been widely used for more than 10 years, but the sensitivity is low, particularly for patients in the early stage. Recently, a new MSA diagnostic criteria was developed.ObjectiveThe objective of the study was to assess and compare the diagnostic utility of the new movement disorder society (MDS) MSA criteria with the 2008 MSA criteria.MethodsThis study included patients diagnosed with MSA between January 2016 and October 2021. All patients underwent regular face-to-face or telephonic follow-ups every year until October 2022. A total of 587 patients (309 males and 278 females) were retrospectively reviewed to compare the diagnostic accuracy of the MDS MSA criteria to that of the 2008 MSA criteria (determined by the proportion of patients categorized as established or probable MSA). Autopsy is the gold standard diagnosis of MSA, which is not available in clinical practice. Thus, we applied the 2008 MSA criteria at the last review as the reference standard.ResultsThe sensitivity of the MDS MSA criteria (93.2%, 95% CI = 90.5–95.2%) was significantly higher than that of the 2008 MSA criteria (83.5%, 95% CI = 79.8–86.6%) (P < 0.001). Additionally, the sensitivity of the MDS MSA criteria was maintained robustly across different subgroups, defined by diagnostic subtype, disease duration, and the type of symptom[s] at onset. Importantly, the specificities were not significantly different between the MDS MSA criteria and the 2008 MSA criteria (P > 0.05).ConclusionThe present study demonstrated that the MDS MSA criteria exhibited good diagnostic utility for MSA. The new MDS MSA criteria should be considered as a useful diagnostic tool for clinical practice and future therapeutic trials.

show abstract

Section: Introductionmentioning

confidence: 99%